Q-omics provides the consensus-scored PCDHB18P profile across patient tissues and cancer cell-line models. PCDHB18P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHB18P is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PCDHB18P RNA expression shows 16,927 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where PCDHB18P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB18P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB18P survival associations across molecular data types. PCDHB18P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB18P RNA expression–survival associations across cancer types. High PCDHB18P expression shows unfavorable associations in BLCA, ACC, THCA, LUAD and STAD, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHB18P RNA expression.
This table summarizes PCDHB18P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHB18P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB18P shows lower tumor expression in THCA, KICH, UCEC, BLCA and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher PCDHB18P RNA expression in tumor versus normal tissue (log2 FC = +0.300, t-test p < 0.001).
This table shows molecular features associated with PCDHB18P in patient tissues and cancer cell lines. In patient samples, PCDHB18P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
